Novo’s New Chairman Urged to Curb Risk After Metsera Drama
The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it.
By Naomi Kresge, Sara Sjolin, Lisa Pham · Bloomberg Markets
The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it.